Updated Recs Aim to Expand Primary Aldosteronism Screening

This article originally appeared here.
Share this content:
Updated Recs Aim to Expand Primary Aldosteronism Screening
Updated Recs Aim to Expand Primary Aldosteronism Screening

MONDAY, May 2, 2016 (HealthDay News) -- The Endocrine Society has issued new guidelines intended to increase screening for primary aldosteronism. The Clinical Practice Guideline was published online March 2 in The Journal of Clinical Endocrinology & Metabolism.

John W. Funder, M.D., Ph.D., from the Hudson Institute of Medical Research in Australia, and colleagues searched for systematic reviews and primary studies to formulate key treatment and prevention recommendations for primary aldosteronism. The quality of evidence and strength of recommendations were described.

The researchers recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio for high-risk groups of patients with hypertension and those with hypokalemia; the condition should be confirmed/excluded using a confirmatory test. All patients with primary aldosteronism are recommended to undergo adrenal computed tomography as the initial study in testing for subtypes and to exclude adrenocortical carcinoma. Using bilateral adrenal venous sampling, an experienced radiologist should establish/exclude unilateral primary aldosteronism; if confirmed, this should be treated by laparoscopic adrenalectomy. Treatment with a mineralocorticoid receptor antagonist is recommended for patients with bilateral adrenal hyperplasia or those unsuitable for surgery.

"The revised guidelines make recommendations and suggestions for the management of primary aldosteronism on the evidence, both scientific and societal," the authors write. "Over the next five years, management should have further evolved."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FDA Panel Has Tie Vote on New Type ...

Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years

Frailty Could Increase Susceptibility for Dementia

Frailty Could Increase Susceptibility for Dementia

Authors say frailty should be considered in clinical care, management of Alzheimer dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »